Publicaciones en colaboración con investigadores/as de Hospital Universitario de Donostia (10)

2024

  1. Anti-miR-873-5p improves alcohol-related liver disease by enhancing hepatic deacetylation via SIRT1

    JHEP Reports, Vol. 6, Núm. 1

  2. Description of clinical and genetic features of 122 patients included in the Spanish Pompe registry

    Neuromuscular Disorders, Vol. 34, pp. 1-8

2021

  1. Anti-miR-518d-5p overcomes liver tumor cell death resistance through mitochondrial activity

    Cell Death and Disease, Vol. 12, Núm. 6

  2. E2F1 and E2F2-mediated repression of CPT2 establishes a lipid-rich tumor-promoting environment

    Cancer Research, Vol. 81, Núm. 11, pp. 2874-2887

  3. Neddylation inhibition ameliorates steatosis in NAFLD by boosting hepatic fatty acid oxidation via the DEPTOR-mTOR axis

    Molecular Metabolism, Vol. 53

2020

  1. Canavan gaixotasuna (aspartoazilasaren gabezia): Euskal Herriko lehen kasuaren eta Europako mutazio berri baten aurkezpena

    Osagaiz: osasun-zientzien aldizkaria, Vol. 4, Núm. 2, pp. 71-78

  2. Multi‐omics integration highlights the role of ubiquitination in ccl4‐induced liver fibrosis

    International Journal of Molecular Sciences, Vol. 21, Núm. 23, pp. 1-19

2019

  1. SUMOylation regulates LKB1 localization and its oncogenic activity in liver cancer

    EBioMedicine, Vol. 40, pp. 406-421

2018

  1. MiR-873-5p acts as an epigenetic regulator in early stages of liver fibrosis and cirrhosis

    Cell Death and Disease, Vol. 9, Núm. 10

2015

  1. Histone deacetylase 4 promotes cholestatic liver injury in the absence of prohibitin-1

    Hepatology, Vol. 62, Núm. 4, pp. 1237-1248